An alteration in BRAF, KIT, or NRAS was identified in 14% (5/37), 10% (4/37), and 10% (4/37) of the patients with AM and 3% (2/55), 19% (11/55), and 10% (6/55) of the patients with MM, respectively. Here, NRAS is linked to acute myeloblastic leukemia with maturation.